Michiel de HAAN
Michiel de Haan has been active in venture capital since 1980 when he founded Atlas Venture in Amsterdam.
During his leadership Atlas developed into a European-American venture capital firm with offices in Amsterdam, Munich, Boston and London.
Atlas Venture has been involved in more than 300 venture backed companies in Information Technology and Life Science .
Michiel's personal venture management activity has always been focussed on Life Science companies in which he held numerous board seats.
Currently he is General Partner of Aescap Venture, Amsterdam that he cofounded in 2005.
Aescap invests in early stage Life Science companies in Europe that have the potential to become world leaders in their field.
Michiel is founding member and past chairman of the European Venture Capital Association ( EVCA ) and cofounder of the European Venture Philanthropy Association ( EVPA ).
Contribution to the panel discussion
The European Commission wishes to support venture capital in its important role in transforming invention and innovation in healthcare into major companies .
Actelion, Crucell, Morphosys, Innogenetics, Galapagos to name a few, are all venture backed start ups and spinouts that today play a extremely important role in healthcare innovation and economic impact in general.
It must be understood that effective venture capital is an artisan industry ( not an institutional one ) that is not only supporting truly innovative entrepreneurs with crucial capital in the most risky phase of their plans, but also with participative management and relationship interaction.
This catalyst role can be strongly enhanced with complimentary EC finance schemes and should not be hampered by EC regulations that originate from their wish to curb the institutional finance and private equity markets.